RIKEN Program for Drug Discovery and Medical Technology Platforms (DMP)
The aim of the RIKEN Program for Drug Discovery and Medical Technology Platforms is to contribute to the identification of new treatments for cancer and other diseases by promoting collaboration within RIKEN for the development of innovative new pharmaceuticals and medical technologies.
The program is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds such as small molecules and antibodies, and the acquisition of intellectual property rights to drugs and technologies that can then be brought to the development phase.
The program also provides support for translational research and the transfer of potential drug candidates to pre-clinical and clinical phases of drug development.
Fields of focus
- 1.Small molecule drugs
- 2.Monoclonal antibody drugs and vaccines
- 3.Cell-based drugs and regenerative medicine
- 4.R&D for the construction of drug discovery and medical technology platforms
- Chemical Bank Unit for Drug Discovery Platform (CSRS)
- Hiroyuki Osada (D.Agr.)
- Drug Discovery Antibody Platform Unit (IMS)
- Toshitada Takemori (M.D., Ph.D.)
- Drug Discovery Structural Biology Platform Unit (BDR)
- Mikako Shirouzu (Ph.D.)
- Drug Discovery Computational Chemistry Platform Unit (BDR)
- Teruki Honma (Ph.D.)
- Drug Discovery Chemistry Platform Unit (CSRS)
- Hiroo Koyama (Ph.D.)
- iPS Cell Research Unit for Drug Discovery (BRC)
- Yukio Nakamura (M.D., Ph.D.)
- Data Intelligence Collaborative Unit for Drug Discovery Platform (MIH)
- Yasushi Okuno (Ph.D.)
W502, West Research Bldg.
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan